1. Home
  2. WVE vs FSLY Comparison

WVE vs FSLY Comparison

Compare WVE & FSLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • FSLY
  • Stock Information
  • Founded
  • WVE 2012
  • FSLY 2011
  • Country
  • WVE Singapore
  • FSLY United States
  • Employees
  • WVE N/A
  • FSLY N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • FSLY Computer Software: Prepackaged Software
  • Sector
  • WVE Health Care
  • FSLY Technology
  • Exchange
  • WVE Nasdaq
  • FSLY Nasdaq
  • Market Cap
  • WVE 915.6M
  • FSLY 1.1B
  • IPO Year
  • WVE 2015
  • FSLY 2019
  • Fundamental
  • Price
  • WVE $6.97
  • FSLY $7.73
  • Analyst Decision
  • WVE Strong Buy
  • FSLY Hold
  • Analyst Count
  • WVE 17
  • FSLY 10
  • Target Price
  • WVE $19.94
  • FSLY $8.44
  • AVG Volume (30 Days)
  • WVE 2.4M
  • FSLY 2.3M
  • Earning Date
  • WVE 11-11-2025
  • FSLY 11-05-2025
  • Dividend Yield
  • WVE N/A
  • FSLY N/A
  • EPS Growth
  • WVE N/A
  • FSLY N/A
  • EPS
  • WVE N/A
  • FSLY N/A
  • Revenue
  • WVE $93,946,000.00
  • FSLY $570,968,000.00
  • Revenue This Year
  • WVE N/A
  • FSLY $12.21
  • Revenue Next Year
  • WVE $10.02
  • FSLY $6.92
  • P/E Ratio
  • WVE N/A
  • FSLY N/A
  • Revenue Growth
  • WVE N/A
  • FSLY 7.43
  • 52 Week Low
  • WVE $5.28
  • FSLY $4.65
  • 52 Week High
  • WVE $16.74
  • FSLY $12.08
  • Technical
  • Relative Strength Index (RSI)
  • WVE 29.71
  • FSLY 57.12
  • Support Level
  • WVE $7.12
  • FSLY $7.29
  • Resistance Level
  • WVE $7.76
  • FSLY $7.90
  • Average True Range (ATR)
  • WVE 0.51
  • FSLY 0.29
  • MACD
  • WVE -0.32
  • FSLY 0.02
  • Stochastic Oscillator
  • WVE 0.57
  • FSLY 79.29

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About FSLY Fastly Inc.

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.

Share on Social Networks: